In addition, our previous study displayed asignificant reduction in the concentration of the membrane-bound aggregationprone Aβ42 in the hippocampal area after triple intravenousinjections of 1 mg/kg SST-scFv8D3.6 Whilethese effects highlighted SST-scFv8D3 as a potential therapeutic optionin the treatment of early Alzheimer’s disease, changes in thelevels of other proteins in the brain resulting from such treatmentneed to be addressed. The gene discussed is SST; the disease is early-onset autosomal dominant Alzheimer disease.